About Bonum Therapeutics
Bonum Therapeutics is a private company based in Seattle, Washington, incorporated in 2021 in Delaware. It has reported $73,135,704 raised in three offerings on Form D since December 2021. Its chief executive is John Mulligan.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Apr 3, 2026 | Apr 17, 2026 | $26,907,396of $32.3M target | 8 | $3.3M | EquityRule 506(b) | Form D ↗ |
| Nov 15, 2022 | Nov 29, 2022 | $45,041,421of $93.0M target | 10 | $4.5M | EquityRule 506(b) | Form D ↗ |
| Dec 8, 2021 | Dec 22, 2021 | $1,186,887of $3.5M target | 5 | $237K | EquityRule 506(b) | Form D ↗ |
| Total, three offerings | $73,135,704 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Bonum Therapeutics's Form D filed Apr 17, 2026.
Samuel Bjork
Executive Chair
Monique Schiersing
Senior Investment Director, Roche Venture
JM
John McKearn
Director
Karl Handelsman
Founder & Managing Partner, Codon Capital, director
NW
MM
Mitchell Mutz
Independent Director
Gaurav Aggarwal
Managing Partner, Vivo Capital and director